



Moderate-Severe Disease

- Liposomal amphotericin B, 3-5 mg/kg/day iv. for 2 weeks,
- followed by oral itraconazole, 400 mg/day for a subsequent duration of **10 weeks** (AII),
- followed by secondary prophylaxis-oral itraconazole 200 mg/day for prevention of recurrence until receive combination ART and have CD4 counts >100 cells/mm³ for ≥6 months.

Mild disease

NNRTIs can slightly decrease blood levels of itraconazole

- oral itraconazole 400 mg/day for 8 weeks (BII)

U.S. Department of Health and Human Services, 2017, at <https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-guidelines/349/penicilliosis>



Alternative drug for primary treatment

- IV voriconazole, 6 mg/kg every 12 hours on day 1 and then 4 mg/kg every 12 hours for at least 3 days, followed by oral voriconazole, 200 mg twice daily for a maximum of 12 weeks.
- Patients with mild disease can be initially treated with oral voriconazole 400 mg twice a day on day 1, and then 200 mg twice daily for 12 weeks (BII).
- The optimal dose of voriconazole for secondary prophylaxis after 12 weeks has not been studied

Non HIV ?????

U.S. Department of Health and Human Services, 2017, at <https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-guidelines/349/penicilliosis>



Table 4 Treatment outcome of penicilliosis marneffei patients with and without HIV infection

Variables	Number of patients (%)		p-values
	HIV-infected patients (N = 116)	HIV-uninfected patients (N = 34)	
Treatment received	102 (87.9)	30 (88.2)	1.000
Medication			0.823
0.6-1.0 mg/kg/day for 2 weeks			
-Amphotericin B then itraconazole 8 to 10 weeks	71 (69.6)	20 (66.7)	
-itraconazole	31 (30.4)	10 (33.3)	
Outcome			0.351
-Recovery	92 (79.3)	24 (70.6)	
-Dead	24 (20.7)	10 (29.4)	
Treatment duration (days) (median, IQR)	84 (84, 90)	180 (84, 180)	<0.001

Penicilliosis marneffei (1), mixed infection with Salmonella enteritidis (1), and hospital-acquired infections (8).

Kawila R, Chalwarith R, Supparatpinyo K BMC Infect Dis. 2019 Oct 5; 19(1):464.



Moderately Severe to Severe Disseminated Disease in AIDS pt

Induction Therapy

- Preferred Therapy: Liposomal amphotericin B at 3 mg/kg IV daily (AI)
- Alternative Therapy: Amphotericin B lipid complex or amphotericin B cholesteryl sulfate complex 3 mg/kg IV daily (AIII)

Duration: For at least 2 weeks or until clinically improved

- Maintenance Therapy: Itraconazole 200 mg PO TID for 3 days, then BID for **at least 12 months** (AII)

[Itraconazole level >1 µg/mL, Itraconazole oral solution is preferred over capsule]

U.S. Department of Health and Human Services, 2017, at <https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-guidelines>





Alternative Therapy in AIDS pt

Note: These recommendations are based on limited clinical data (for patients intolerant to itraconazole who are only moderately ill)

- Posaconazole 400 mg PO BID (**BIII**)
- Voriconazole 400 mg PO BID for 1 day, then 200 mg PO BID (**BIII**)
- Fluconazole 800 mg PO daily (**CII**)

U.S. Department of Health and Human Services, 2017, at <https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/949/penicilliosis>



Disseminated disease

- Amphotericin B 0.6-0.7 mg/kg/day for 1-2 weeks,
- Oral itraconazole, 200 mg three times daily for 3 days followed by itraconazole 200 mg bid for at least **10–12** weeks
- Maintenance of itraconazole of at least 200 mg/day is recommended

Alternative Therapy

- Amphotericin B 0.4-0.5 mg/kg/day for 10-12 weeks
- Fluconazole 800 mg PO daily

แนวทางการตรวจรักษาและป้องกันการติดเชื้อเอชไอวี ประเทศไทย ปี 2560: 2560:18



Indication for Primary Prophylaxis

- All HIV-infected patients with CD4 counts <100 cells/mm³ who reside or stay for a **long period in northern Thailand, Vietnam, and southern China**, and particularly in rural areas, should be administered primary prophylaxis (**BI**).
- The preferred drug for prophylaxis is **oral itraconazole, 200 mg/day (BI)**. An alternative drug is **oral fluconazole 400 mg once weekly (BII)**

“A double-blind, placebo-controlled study from Chiang Mai, Thailand, demonstrated that **oral itraconazole, 200 mg daily** for primary prophylaxis, significantly reduced occurrence of systemic fungal infections (cryptococcosis and penicilliosis) in HIV-infected patients with CD4 counts <200 cells/mm³. Fluconazole may also be effective prophylaxis”

<https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/949/penicilliosis>





- Primary prophylaxis สำหรับป้องกัน cryptococcosis, penicilliosis, histoplasmosis ในผู้ติดเชื้อเอชไอวีที่มีข้อบ่งชี้ใน อาจพิจารณาให้เฉพาะใน รายที่ไม่สามารถ เริ่มการรักษาด้วยยาด้านเอชไอวีได้เร็ว (optional)

Primary prophylaxis

- ในผู้ใหญ่ที่มี CD4 < 100 cells/mm³ (penicilliosis) และ 150 cells/mm³ (histoplasmosis) ที่อยู่ในพื้นที่ที่มีเชื้อนี้ชุกชุม
- itraconazole 200 มก. กินวันละครั้ง (หากใช้ itraconazole ป้องกัน histoplasmosis หรือ penicilliosis แล้ว ไม่ต้องให้ fluconazole เพื่อป้องกัน cryptococcosis อีก)
- การหยุดให้ยาป้องกัน ผู้ที่ได้ยาด้านเอชไอวีและ CD4 > 100 cells/mm³ (penicilliosis) และ 150 cells/mm³ (histoplasmosis) นานกว่า 6 เดือนสามารถหยุดยาได้

แนวทางการตรวจรักษาและป้องกันการติดเชื้อเอชไอวี ประเทศไทย ปี 2560





Thomas F. Patterson,^{1,2} George R. Thompson III,³ David W. Denning,⁴ Jay A. Fishman,⁵ Susan Hadley,⁶ Roxel Herberichs,⁷ Dimitrios P. Kontoyannis,⁸ Kiron A. Mori,⁹ Vicki A. Morrison,¹⁰ M. Hong Nguyen,¹¹ Brian H. Segal,¹² William J. Steinbach,¹³ David A. Stevens,¹⁴ Thomas J. Walsh,¹⁵ John R. Wingard,¹⁶ Jo-Anne H. Young,¹⁷ and John E. Bennett¹⁸

Prophylaxis-primary treatment

Posaconazole

- Oral suspension: 200 mg TID
- Tablet: 300 mg BID on day 1, then 300 mg daily
- IV: 300 mg BID on day 1, then 300 mg daily

Prophylaxis-alternative treatment

- Voriconazole (200 mg PO BID)
- Itraconazole suspension (200 mg PO every 12 h)
- Micafungin (50–100 mg/day)
- Caspofungin (50 mg/day)



Thomas F. Patterson,^{1,2} George R. Thompson III,³ David W. Denning,⁴ Jay A. Fishman,⁵ Susan Hadley,⁶ Roxel Herberichs,⁷ Dimitrios P. Kontoyannis,⁸ Kiron A. Mori,⁹ Vicki A. Morrison,¹⁰ M. Hong Nguyen,¹¹ Brian H. Segal,¹² William J. Steinbach,¹³ David A. Stevens,¹⁴ Thomas J. Walsh,¹⁵ John R. Wingard,¹⁶ Jo-Anne H. Young,¹⁷ and John E. Bennett¹⁸

Empiric therapy

- Liposomal AmB (3 mg/kg/day IV)
- Caspofungin (70 mg day 1 IV and 50 mg/day IV thereafter)
- Micafungin (100 mg day)
- Voriconazole (6 mg/kg IV every 12 h for 1 day, followed by 4 mg/kg IV every 12 h; oral therapy can be used at 200–300 mg every 12 h or 3–4 mg/kg q 12 h)



Patterson et al. CID 2016



Thomas F. Patterson,^{1,2} George R. Thompson III,³ David W. Denning,⁴ Jay A. Fishman,⁵ Susan Hadley,⁶ Roxel Herberichs,⁷ Dimitrios P. Kontoyannis,⁸ Kiron A. Mori,⁹ Vicki A. Morrison,¹⁰ M. Hong Nguyen,¹¹ Brian H. Segal,¹² William J. Steinbach,¹³ David A. Stevens,¹⁴ Thomas J. Walsh,¹⁵ John R. Wingard,¹⁶ Jo-Anne H. Young,¹⁷ and John E. Bennett¹⁸

Preemptive therapy

High-risk population with evidence of invasive fungal infection (eg, pulmonary infiltrate or positive GM assay result)

- Liposomal AmB (3 mg/kg/day IV)
- Caspofungin (70 mg day 1 IV and 50 mg/day IV thereafter)
- Micafungin (100 mg day)
- Voriconazole



Patterson et al. CID 2016